Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time
Edgewise Therapeutics (NASDAQ: EWTX) has announced a webcast event scheduled for April 2, 2025, at 8:30 am ET to present top-line results from their Phase 2 CIRRUS-HCM trial of EDG-7500 in patients with hypertrophic cardiomyopathy (HCM). The 28-day trial evaluated EDG-7500 in both obstructive and nonobstructive HCM patients.
The webcast will feature presentations from the management team alongside two CIRRUS-HCM investigators, described as world leaders in HCM patient care. The event will include an accompanying slide presentation, with registration available through the Edgewise events page.
Edgewise Therapeutics (NASDAQ: EWTX) ha annunciato un evento in webcast programmato per il 2 aprile 2025, alle 8:30 ET per presentare i risultati preliminari del loro trial di Fase 2 CIRRUS-HCM su EDG-7500 in pazienti con cardiomiopatia ipertrofica (HCM). Il trial di 28 giorni ha valutato EDG-7500 sia in pazienti con HCM ostruttiva che non ostruttiva.
Il webcast presenterà relazioni del team di gestione insieme a due investigatori del CIRRUS-HCM, descritti come leader mondiali nella cura dei pazienti con HCM. L'evento includerà una presentazione di diapositive, con registrazione disponibile attraverso la pagina eventi di Edgewise.
Edgewise Therapeutics (NASDAQ: EWTX) ha anunciado un evento por webcast programado para el 2 de abril de 2025, a las 8:30 a.m. ET para presentar los resultados preliminares de su ensayo de Fase 2 CIRRUS-HCM de EDG-7500 en pacientes con cardiomiopatía hipertrófica (HCM). El ensayo de 28 días evaluó EDG-7500 en pacientes con HCM obstructiva y no obstructiva.
El webcast contará con presentaciones del equipo de gestión junto con dos investigadores de CIRRUS-HCM, descritos como líderes mundiales en el cuidado de pacientes con HCM. El evento incluirá una presentación de diapositivas, con registro disponible a través de la página de eventos de Edgewise.
엣지와이즈 테라퓨틱스 (NASDAQ: EWTX)는 2025년 4월 2일 오전 8시 30분 ET에 하이퍼트로픽 심근병증(HCM) 환자를 위한 EDG-7500의 2상 CIRRUS-HCM 시험의 주요 결과를 발표하는 웹캐스트 이벤트를 예정하고 있다고 발표했습니다. 28일간의 시험은 HCM의 폐쇄형 및 비폐쇄형 환자 모두에서 EDG-7500을 평가했습니다.
웹캐스트에는 HCM 환자 치료의 세계적 권위자로 묘사된 CIRRUS-HCM의 두 명의 연구자와 함께 경영진 팀의 발표가 포함될 것입니다. 이 이벤트에는 슬라이드 발표가 포함되며, 엣지와이즈 이벤트 페이지를 통해 등록할 수 있습니다.
Edgewise Therapeutics (NASDAQ: EWTX) a annoncé un événement en webcast prévu pour le 2 avril 2025 à 8h30 ET afin de présenter les résultats préliminaires de leur essai de Phase 2 CIRRUS-HCM sur EDG-7500 chez des patients atteints de cardiomyopathie hypertrophique (HCM). L'essai de 28 jours a évalué EDG-7500 chez des patients HCM obstructifs et non obstructifs.
Le webcast comportera des présentations de l'équipe de direction ainsi que de deux chercheurs CIRRUS-HCM, décrits comme des leaders mondiaux dans le soin des patients HCM. L'événement comprendra une présentation de diapositives, avec une inscription disponible via la page événements d'Edgewise.
Edgewise Therapeutics (NASDAQ: EWTX) hat ein Webcast-Event angekündigt, das für den 2. April 2025 um 8:30 Uhr ET geplant ist, um die vorläufigen Ergebnisse ihrer Phase 2 CIRRUS-HCM-Studie zu EDG-7500 bei Patienten mit hypertropher Kardiomyopathie (HCM) zu präsentieren. Die 28-tägige Studie bewertete EDG-7500 sowohl bei obstruktiven als auch bei nicht-obstruktiven HCM-Patienten.
Der Webcast wird Präsentationen des Management-Teams sowie von zwei CIRRUS-HCM-Forschern umfassen, die als weltweite Experten in der Versorgung von HCM-Patienten beschrieben werden. Die Veranstaltung wird eine begleitende Folienpräsentation beinhalten, mit Registrierung über die Edgewise-Veranstaltungsseite.
- None.
- None.
About EDG-7500
EDG-7500 is a novel oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with hypertrophic cardiomyopathy (HCM) and other diseases of diastolic dysfunction. To learn more about CIRRUS-HCM, visit clinicaltrials.gov, NCT06347159 (Phase 2).
About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn, X, Facebook and Instagram.
This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.
Edgewise Contacts
Investors:
Michael Carruthers, Chief Financial Officer
ir@edgewisetx.com
Media:
Maureen Franco, VP Corporate Communications
media@edgewisetx.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-to-host-webcast-event-to-discuss-top-line-results-from-phase-2-cirrus-hcm-28-day-trial-of-edg-7500-in-hypertrophic-cardiomyopathy-hcm-on-wednesday-april-2-at-830-am-eastern-time-302412513.html
SOURCE Edgewise Therapeutics
FAQ
When will Edgewise Therapeutics (EWTX) release the Phase 2 CIRRUS-HCM trial results?
What is the duration of the EWTX CIRRUS-HCM trial for EDG-7500?
Which patient types were included in the EWTX Phase 2 CIRRUS-HCM study?
Who will present the EWTX CIRRUS-HCM trial results?
